The present invention provides an inhalable formulation comprising a ligand conjugated oligonucleotide and particles of a physiologically acceptable pharmacologically-inert carrier.

A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogs.

Disclosed herein are methods of treating a disease in a subject which is the consequence of previous exposure of the subject to a virus, particularly SARS-CoV-2, the method comprising administration of an effective amount of one or more agents to the subject.

The present invention relates to a method of forming a concentrated solution of first and second pharmacologically active ingredients which involves: providing a solid eutectic composition of the first and second pharmacologically active ingredients; providing a first solvent; and dissolving the eutectic composition in the first solvent; wherein the first and second pharmacologically active ingredients are independently selected from β2 agonists, muscarinic antagonists, anticholinergics, corticosteroids, methylxanthine compounds and salts, esters, polymorphs, hydrates or solvates thereof. A solution obtainable by this method is also described, along with an ampoule for a nebuliser and a pressurised metered dose inhaler comprising the solution. The solution is useful in the treatment of respiratory diseases.

In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation.

The invention discloses spray-dried compositions for inhalation and methods for preparing such powder compositions. The compositions of the invention are produced by spray-drying taurine under conditions that (i) retain the physical and chemical stability of the composition during spray drying and upon storage, (ii) protect the powder composition from aggregation and (iii) provide particles suitable for aerosolisation.

Use of an interferon (INF), whether Type I (e.g. interferon-alpha, interferon-beta, etc.), Type II (e.g. interferon-gamma) and/or Type III (e.g. interferon-lamda), for inhibiting and/or preventing coronavirus infection in people, including but not limited to those people at risk of exposure to COVID 19 and/or variants thereof.

A composition for sequestering a pathogen, for example, viral particles of a target virus in the respiratory tract of a subject is provided. The composition comprises an effective amount of sequestering particles having a protein binding agent on the surface of the sequestering particles. The protein binding agent binds a pathogenic surface protein, for example, capsid protein on the surface of the viral particles. The sequestering particles and the target pathogen, for example, viral particles, form aggregates. Also provided is the use of the composition for sequestering a target pathogen, for example, viral particles of a target virus, in the respiratory tract of a subject.